Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant either must have ceased lactating at Screening; or if still lactating at Screening, must have already fully and permanently weaned their infant(s) from breastmilk; or if still actively breastfeeding at Screening, must agree to cease giving breastmilk to their infant(s) prior to receiving study drug.~* Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).~* Participant was less than or equal to (\<=) six months postpartum.~* Participant must be amenable to intravenous therapy.~Key Exclusion Criteria:~* Active psychosis.~* Attempted suicide associated with index case of postpartum depression.~* Medical history of seizures.~* Medical history of bipolar disorder.~Note: suicidal ideation was not an exclusion. Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received infusion rates of placebo matched to SAGE-547.
- SAGE-547 (Type: EXPERIMENTAL): Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).